SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-22-023142
Filing Date
2022-02-14
Accepted
2022-02-14 17:07:15
Documents
2
Group Members
JEREMY C. GREEN

Document Format Files

Seq Description Document Type Size
1 SC 13G/A tm226094d3_sc13ga.htm SC 13G/A 61833
2 EXHIBIT 99.1 tm226094d3_ex99-1.htm EX-99.1 5229
  Complete submission text file 0001104659-22-023142.txt   68856
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

IRS No.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-37761 | Film No.: 22634480
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129
Business Address ONE LETTERMAN DRIVE BUILDING D, SUITE D3-300 SAN FRANCISCO CA 94129 415-489-9980
Redmile Group, LLC (Filed by) CIK: 0001425738 (see all company filings)

IRS No.: 208592298 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A